Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology
- PMID: 24379304
- PMCID: PMC3977608
- DOI: 10.1093/jac/dkt508
Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology
Abstract
The burden of human disease related to medically important fungal pathogens is substantial. An improved understanding of antifungal pharmacology and antifungal pharmacokinetics-pharmacodynamics has resulted in therapeutic drug monitoring (TDM) becoming a valuable adjunct to the routine administration of some antifungal agents. TDM may increase the probability of a successful outcome, prevent drug-related toxicity and potentially prevent the emergence of antifungal drug resistance. Much of the evidence that supports TDM is circumstantial. This document reviews the available literature and provides a series of recommendations for TDM of antifungal agents.
Keywords: fungal diseases; fungal pathogens; triazoles.
References
-
- Bruggemann RJ, Donnelly JP, Aarnoutse RE, et al. Therapeutic drug monitoring of voriconazole. Ther Drug Monit. 2008;30:403–11. - PubMed
-
- Hope WW, Billaud EM, Lestner J, et al. Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis. 2008;21:580–6. - PubMed
-
- Lewis RE. Antifungal therapeutic drug monitoring. Curr Fungal Infect Rep. 2010;4:158–67.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
